Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lyndal Stoutin

Interventional Pain Medicine Lewiston, ID Medical Doctor

NPI 1245240761 CMS profile 740533

2841 Juniper Dr, Lewiston, ID 83501

Open in the dashboard

General payments

$2,886

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lyndal Stoutin of Lewiston, ID is reported in the CMS Open Payments database as having received $2,886 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $343 14
2024 General $334 9
2023 General $109 2
2022 General $405 10
2021 General $201 6
2020 General $1,411 10
2019 General $83 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lyndal Stoutin
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Lyndal Stoutin were reported at $343. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Lyndal Stoutin Interventional Pain Medicine median Middle half National median
2019 $83 $684 $216–$2,079 $163
2020 $1,411 $382 $122–$1,109 $114
2021 $201 $552 $167–$1,554 $132
2022 $405 $605 $187–$1,924 $149
2023 $109 $671 $195–$1,915 $160
2024 $334 $684 $206–$1,837 $164
2025 $343 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,107 37 payments
  2. Medtronic, Inc. $247 4 payments
  3. Vertos Medical, Inc. $156 4 payments
  4. Saluda Medical Americas, Inc. $89 3 payments
  5. Relievant Medsystems, Inc. $56 1 payment
  6. Collegium Pharmaceutical, Inc. $54 1 payment
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $54 1 payment
  8. GRT US Holding, Inc. $45 1 payment
  9. Stryker Corporation $41 1 payment
  10. Pfizer Inc. $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,751 51 payments
  2. Travel and Lodging $1,135 4 payments
Products named General payments · program years 2019–2025
  1. SUPERION $1,381 8 payments
  2. INTELLIS ADAPTIVESTIM $181 2 payments
  3. mild Device Kit $156 4 payments
  4. General - Pain Management General - Pain Management_NMD $118 5 payments
  5. Intracept RF Probe $117 8 payments
  6. General - Therapies $97 1 payment
  7. Evoke $89 3 payments
  8. GENERAL - PAIN MANAGEMENT Pain Management $66 4 payments
  9. Intracept Pain $56 1 payment
  10. Intracept Pain $56 1 payment
  11. Other $473 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

344

Median for Interventional Pain Management: 1,220

Drug cost

$7,200

Median for Interventional Pain Management: $39,344

Branded share of claims

16.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fentanyl Generic 12 $2,351
Pregabalin Generic 71 $1,136
Duloxetine Hcl Generic 82 $1,074
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 43 $650
Buprenorphine Hcl Generic 12 $579
Nortriptyline Hcl Generic 36 $448
Gabapentin Generic 13 $259
Methadone Hcl Generic 12 $210
Tizanidine Hcl Generic 14 $193
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 14 $142

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record